|
LIVE NCPD WEBINARS: July 15 and August 26, 2021
Summer Oncology Nursing SeriesA Complimentary NCPD-Accredited Virtual CurriculumGynecologic Cancers
Register for these complimentary events with the “Register Now ” button above, All events moderated by Thursday, July 15, 2021 from 5:00 PM – 6:00 PM Eastern Time
Krishnansu S Tewari, MD
Professor and Division Director Division of Gynecologic Oncology University of California, Irvine Irvine, California
Courtney Arn, CNP
The James Cancer Hospital and Solove Research Institute The Ohio State University Columbus, Ohio
Thursday, August 26, 2021 from 5:00 PM – 6:00 PM Eastern Time
Thomas J Herzog, MD
Paul and Carolyn Flory Professor Deputy Director, University of Cincinnati Cancer Center Vice-Chair, Quality and Safety Department of Obstetrics and Gynecology University of Cincinnati Medical Center Associate Director, GOG Partners Cincinnati, Ohio
Kimberly A Spickes, MNSc, RN, APRN, OCN, ACNP-BC
Nurse Practitioner UAMS Division of Gynecologic Oncology University of Arkansas for Medical Sciences Little Rock, Arkansas
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline and Merck. Topics to Be Discussed
Target Audience
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCPD Designation Statements Each educational activity for 1 contact hour is provided by RTP. Each activity is awarded 1 ANCC pharmacotherapeutic contact hour. To obtain a certificate of completion and receive credit for each event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity. Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.researchtopractice.com/Webinars/ONS2021/MTP/GynOnc/ILNA Unlabeled/Unapproved Uses Notice There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified. Content Validation and Disclosures RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — Ms Arn and Ms Spickes have no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Herzog – Advisory Committee: Aravive Inc, AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Gradalis Inc, GlaxoSmithKline, Merck; Data and Safety Monitoring Board/Committee: Corcept Therapeutics, Incyte Corporation. Dr Tewari – Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Tesaro, A GSK Company; Contracted Research (to Institution): Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Merck, Tesaro, A GSK Company. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc. RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose. SupportersThese activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline and Merck. |